RT Generic
T1 Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients
A1 Zarzuelo-Romero, Maria Jose
A1 Perez-Ramirez, Cristina
A1 Cura, Yasmin
A1 Carrasco-Campos, Maria Isabel
A1 Marangoni-Iglecias, Luciana Maria
A1 Ramirez-Tortosa, Maria Carmen
A1 Jimenez-Morales, Alberto
K1 multiple sclerosis
K1 glatiramer acetate
K1 myelin basic protein
K1 response
K1 treatment
K1 polymorphisms
K1 pharmacogenetics
K1 medicine personalized
K1 Genome-wide association
K1 Myelin basic-protein
K1 Regulatory t-cells
K1 Treatment response
K1 Human-chromosome
K1 Disease-activity
K1 Interferon-beta
K1 Mutations cause
K1 Double-blind
K1 Expression
AB Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of autoimmune origin, in which inflammation and demyelination lead to neurodegeneration and progressive disability. Treatment is aimed at slowing down the course of the disease and mitigating its symptoms. One of the first-line treatments used in patients with MS is glatiramer acetate (GA). However, in clinical practice, a response rate of between 30% and 55% is observed. This variability in the effectiveness of the medication may be influenced by genetic factors such as polymorphisms in the genes involved in the pathogenesis of MS. Therefore, this review assesses the impact of genetic variants on the response to GA therapy in patients diagnosed with MS. The results suggest that a relationship exists between the effectiveness of the treatment with GA and the presence of polymorphisms in the following genes: CD86, CLEC16A, CTSS, EOMES, MBP, FAS, TRBC1, IL1R1, IL12RB2, IL22RA2, PTPRT, PVT1, ALOX5AP, MAGI2, ZAK, RFPL3, UVRAG, SLC1A4, and HLA-DRB1*1501. Consequently, the identification of polymorphisms in these genes can be used in the future as a predictive marker of the response to GA treatment in patients diagnosed with MS. Nevertheless, there is a lack of evidence for this and more validation studies need to be conducted to apply this information to clinical practice.
PB Mdpi
YR 2021
FD 2021-10-01
LK https://hdl.handle.net/10668/26323
UL https://hdl.handle.net/10668/26323
LA en
DS RISalud
RD Apr 12, 2025